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Cytokine mRNA levels were assessed in Burkholderia pseudomallei-susceptible BALB/c mice and B. pseudoma-
llei-resistant C57BL/6 mice following administration of a sublethal dose of less virulent (LV) B. pseudomallei,
a candidate immunogen tested for protection against a highly virulent (HV) challenge. Compared on the basis
of the bacterial loads, the cytokine patterns induced by HV and LV B. pseudomallei were similar, involving
gamma interferon, interleukin-10, and other cytokines. Partial cross-protection between B. pseudomallei strains
is shown to be associated with cytokine profiles involving both type 1 and type 2 cytokines.
Melioidosis is a potentially acute fulminating disease of hu-
mans and animals caused by the gram-negative intracellular
bacterium Burkholderia pseudomallei (36). Infection occurs by
subcutaneous inoculation of contaminated soil or surface wa-
ter and can result in latent infection or a diverse range of
clinical presentations (6). As recently reported by Currie et al.
(8), recrudescence of disease may occur years after initial ex-
posure, which suggests that the immune responses induced
may not be effective for clearance of the organism. Differences
in host and pathogen virulence factors are known to be impor-
tant in determining disease severity (33). Gamma interferon
(IFN-) plays a critical role in innate host resistance during
primary infection (26), but mechanisms of adaptive immunity
have not been widely studied. BALB/c mice are susceptible to
infection with highly virulent (HV) B. pseudomallei, whereas
C57BL/6 mice are relatively resistant (17). Cytokine responses
following an HV B. pseudomallei challenge (34) are unlike
those seen in other models of intracellular infection, and re-
sistance and susceptibility do not correlate with divergent cy-
tokine profiles commonly associated with development of dis-
tinct T helper cell subsets. Instead, early cytokine profiles are
similar in BALB/c and C57BL/6 mice, with the only demon-
strated difference being in the magnitude of the cytokine re-
sponse (34). Responses involving a similar range of cytokines
have been reported in patients (4, 11, 31).
Characterization of less virulent (LV) strains of B.
pseudomallei (12, 13, 35) allows us to determine their potential
as candidate immunogens for induction of adaptive immunity
against HV B. pseudomallei. In models of infection with other
intracellular pathogens (3, 5, 22, 27, 28, 29), cytokine responses
are dependent upon the level of virulence of the challenge
strain. The present study investigated the influence of B.
pseudomallei virulence on disease progression and cytokine
responses in melioidosis. Cytokine profiling of the spleen and
liver was carried out by reverse transcription-PCR, and bacte-
rial growth in the blood, liver, and spleen was determined.
Immunization experiments were performed by using LV B.
pseudomallei as a candidate immunogen for protection against
an HV challenge to analyze the relationship between cytokine
responses and immunity to B. pseudomallei.
The B. pseudomallei strains used were NCTC 13178 (HV)
and NCTC 13179 (LV). The virulence of the strains has been
described previously (33). B. pseudomallei strain ATCC 23343
was used as a reference strain in immunization experiments.
For cytokine studies, C57BL/6 and BALB/c mice (8 to 16
weeks old) were administered 25 CFU of either HV or LV B.
pseudomallei in 200 l of phosphate-buffered saline (PBS)
intravenously (i.v.). At various times following inoculation, five
mice per group were euthanized with CO2 and the bacterial
load in the blood was determined (17). The liver and spleen
were excised, and one half was used to determine the bacterial
load (17) while the other half was stored at 80°C until RNA
extraction. A second model of primary infection was estab-
lished with a larger inoculum (6  104 CFU) of LV B.
pseudomallei. This model allowed a comparison of HV and LV
B. pseudomallei at equivalent bacterial loads. RNA was ex-
tracted from the liver with TRIZOL reagent (Life Technolo-
gies) (7, 34) and from the spleen with SV total RNA isolation
spin columns (Promega). DNase treatment, RNA quantifica-
tion, reverse transcription, and PCR with cytokine-specific
primers were performed as previously described (34). For li-
popolysaccharide-induced CXC chemokine (LIX), primer se-
quences were designed with OLIGO v. 5 software (24) and
PCR parameters were optimized with a plasmid containing
LIX cDNA, which was transformed into competent Esche-
richia coli strain JM109 as previously described (14, 25). The
primers 5 TCC AGC TCG CCA TTC A 3 (sense) and 5 TCC
GCT TAG CTT TCT TTT TG 3 (antisense) were designed to
amplify a 319-bp LIX product. LIX PCR products were gel
purified with a QIAQUICK gel extraction kit (Qiagen) and
sequenced with Big Dye Terminator kit (Perkin-Elmer) on an
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FIG. 1. Growth of HV B. pseudomallei NCTC 13178 (A) and LV B. pseudomallei NCTC 13179 (25-CFU [B] and 6  104-CFU [C] challenges)
in BALB/c and C57BL/6 mice. Results are shown as the mean bacterial load (log10 CFU per milliliter) of five mice  the standard error of the
mean. Significant differences (P  0.01) are indicated by arrows. b, BALB/c mouse death; c, C57BL/6 mouse death.
3954 NOTES INFECT. IMMUN.
 o
n
 O
ctober 13, 2015 by University of Queensland Library
http://iai.asm
.org/
D
ow
nloaded from
 
ABI 310 sequencer (Perkin-Elmer). Sequences were checked
for homology with previously described gene sequences for
LIX (30). The PCR was repeated twice for three separately
prepared cDNA samples.
For immunization experiments, groups of 10 mice were ad-
ministered either PBS (nonimmunized) or 0.1 50% lethal dose
(LD50) of LV B. pseudomallei NCTC 13179 or reference strain
ATCC 23343 (33). Two weeks later, mice were challenged with
one of three different doses of HV B. pseudomallei NCTC
13178 (10 LD50s, 1 LD50, or 0.1 LD50). Additional control
groups received PBS (negative controls). Another series of five
mice were immunized and challenged as already described and
subsequently used to determine the bacterial load in the spleen
at 72 h after a secondary challenge. Statistical analysis of bac-
terial load data was performed with a two-tailed Student t test
for independent samples. Data are expressed as the mean 
the standard error of the mean. Mortalities in immunized
versus nonimmunized groups were analyzed by the Mann-
Whitney U test. P values of 0.01 were considered significant.
HV B. pseudomallei replicated exponentially in the blood,
livers, and spleens of BALB/c mice until host death at 72 h
(Fig. 1A). LV B. pseudomallei (25 CFU) was effectively con-
tained in all of the organs (Fig. 1B; data not shown). In mice
administered 6  104 CFU, exponential growth of LV B.
pseudomallei occurred in BALB/c mice until 72 h, in contrast to
C57BL/6 mice, which reduced the challenge inoculum (Fig.
FIG. 2. Production of cytokine mRNA in livers of BALB/c and
C57BL/6 mice infected i.v. with either 25 CFU of HV B. pseudomallei
NCTC 13178 (a) or 6  104 CFU of LV B. pseudomallei NCTC 13179
(b). The values on the left are the molecular sizes of the markers in
lanes M in kilodaltons.
FIG. 3. Production of cytokine mRNA in spleens of BALB/c and C57BL/6 mice infected i.v. with either 25 CFU of HV B. pseudomallei NCTC
13178 (a), 25 CFU of LV B. pseudomallei NCTC 13179 (b), or 6  104 CFU of B. pseudomallei NCTC 13179 (c). The values on the left are the
molecular sizes of the markers in lanes M in kilodaltons.
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1C). BALB/c mice that survived the early phase of infection
rapidly reduced the bacterial load (Fig. 1C). The reduction in
the bacterial load of BALB/c mice that survived the high-level
challenge with LV B. pseudomallei suggests the potential for
the development of an appropriate immune response in these
innately susceptible mice. Due to progressive deaths of
BALB/c mice, the day 14 data (Fig. 1C) represent one mouse.
Cytokine responses in the liver were most pronounced in
mice challenged with either HV B. pseudomallei or the larger
dose of LV B. pseudomallei (Fig. 2). Responses in the liver
involved IFN-, tumor necrosis factor alpha (TNF-	), inter-
leukin-1
 (IL-1
), IL-6, and IL-10 (Fig. 2) and correlated with
the bacterial load (Fig. 1). In mice administered 25 CFU of LV
B. pseudomallei, absence of a detectable cytokine responses in
the liver was associated with a light bacterial load (data not
shown). This indicates a requirement for a substantial B.
pseudomallei load in the liver before induction of a local cyto-
kine responses. LIX mRNA was detected in the livers of
BALB/c, but not C57BL/6, mice during infection (Fig. 2). No
mRNA for IL-2 or IL-4 was detected in the livers of mice
following a challenge with B. pseudomallei (data not shown).
In the spleen, cytokine responses involved IFN-, TNF-	,
IL-1
, IL-4, and IL-12 (p40 results are shown, but similar
results were obtained with p35) and also correlated with the
bacteria load (Fig. 1). LIX mRNA was detected in the spleens
of BALB/c, but not C57BL/6, mice infected with HV B.
pseudomallei (Fig. 3). The TNF-	 and IL-12 responses in the
spleens of C57BL/6 mice infected with 6  104 CFU of LV B.
pseudomallei (Fig. 3) did not correlate with the bacterial load
(Fig. 1). Instead, mRNAs for TNF-	, IL-12, and IL-4 in these
mice were not detected until 48 to 96 h (Fig. 3), when the
bacterial load was 101 CFU/ml (Fig. 1). IL-4 also demon-
FIG. 4. LV B. pseudomallei NCTC 13179 and reference strain ATCC 23343 confer partial protection against HV B. pseudomallei NCTC 13178
(10-LD50 challenge data are shown). Significant differences in mortality (A) between mice immunized with LV B. pseudomallei NCTC 13179 and
nonimmunized controls are indicated (, P  0.0001). The bacterial loads in the spleens of mice immunized with either LV B. pseudomallei NCTC
13179 or ATCC 23343 and rechallenged with HV B. pseudomallei demonstrate partial protection rather than sterilizing immunity (B). Although
the bacterial loads of immunized C57BL/6 mice were, on average, lighter than those of nonimmunized controls, these differences were not
statistically significant (, P  0.084 for NCTC 13179 and P  0.05 for ATCC 23343).
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strated delayed induction kinetics in the spleens of BALB/c
mice challenged with 6  104 CFU of LV B. pseudomallei (Fig.
3). IL-2 mRNA was not detected in the spleens of mice of
either strain (data not shown). Twenty-five CFU of LV B.
pseudomallei induced cytokine responses in the spleen that
were similar but less pronounced than those induced by HV B.
pseudomallei. The association between the cytokine mRNAs
and the bacterial loads in the spleens of these mice did not
follow the same trend as that observed with HV B. pseudoma-
llei. For example, responses in BALB/c mice at 48 to 96 h
coincided with bacterial loads of 102 CFU/ml. Equivalent
bacterial loads in the liver at 48 to 96 h were not associated
with cytokine responses (data not shown). In contrast to
BALB/c mice, C57BL/6 mice infected with 25 CFU of LV B.
pseudomallei demonstrated no increase in splenic IL-10
mRNA (Fig. 3). Preferential expression of IL-10 in BALB/c
mice suggests a possible role for this cytokine in innate sus-
ceptibility to B. pseudomallei infection.
Partial immunoprotection was demonstrated in mice immu-
nized with either NCTC 13179 or reference strain ATCC
23343 (Fig. 4A). Immunized mice did not develop symptoms of
disease prior to a secondary challenge, despite the recovery of
viable B. pseudomallei from the majority of the animals at day
14. Significantly better protection was obtained with NCTC
13179 (P  0.0001) than with ATCC 23343 (P  0.143). Bac-
terial load data from immunized mice (Fig. 4B) confirmed
partial, rather than sterilizing, immunity. Bacterial loads at
72 h after a secondary challenge of mice immunized with either
NCTC 13179 or ATCC 23343 were not significantly different
from those of nonvaccinated controls (Fig. 4B). These studies,
however, cannot discriminate which strain is the one cultured
after a secondary challenge, and hence, it is possible that an
HV challenge could change host immunity so that increased
replication of LV B. pseudomallei may occur.
This study demonstrates an overall similarity between the
cytokine profiles induced by B. pseudomallei strains with con-
trasting levels of virulence when compared on the basis of
bacterial loads. These observations are in contrast to reports
on other intracellular pathogens (2, 5, 15, 21, 27, 29). This
study also demonstrates an association between these re-
sponses and partial cross-protection of mice immunized with
LV B. pseudomallei and challenged with HV B. pseudomallei.
Early IFN- and IL-12 responses in the spleens of immunized
mice, combined with low-level persistence of viable LV B.
pseudomallei, were considered potentially beneficial for the
stimulation of a more effective host response for adaptive im-
munity against HV B. pseudomallei. Although immunized mice
demonstrated significantly better survival after a subsequent
challenge with HV B. pseudomallei than did nonimmunized
animals, the protection was not sterilizing, as evidenced by the
recovery of high numbers of bacteria from the spleen. Also,
even though the cytokine patterns induced by HV and LV B.
pseudomallei are similar, the magnitude of the response to LV
B. pseudomallei in the spleen does not simply reflect the bac-
terial load within the tissue, as predicted on the basis of a
model of HV B. pseudomallei infection (34). Although the lack
of IL-2 mRNA in the spleens of mice during B. pseudomallei
infection cannot be explained, these observations are consis-
tent with recent reports on other intracellular pathogens (10,
18, 20).
High levels of IL-8 have been demonstrated in patients pre-
senting with acute melioidosis (11). A related chemokine in
mice is LIX (23, 30, 37). Detection of LIX in BALB/c, but not
C57BL/6, mice suggests that LIX may play a role in innate
susceptibility to B. pseudomallei infection. To our knowledge,
there have been only two previous reports of LIX responses in
mice following bacterial infection (19, 32). Lauw et al. (16)
demonstrated a limited number of neutrophil-chemoattractant
chemokines other than IL-8 in patients infected with B.
pseudomallei. Hence, neutrophil-chemoattractant chemokines
other than LIX (e.g., ENA-78) may play an important role in
the immune response to B. pseudomallei infection. Barnes et al.
(1) recently demonstrated diverse chemokine responses in
mice infected with B. pseudomallei. The ability of B. pseudoma-
llei to survive and replicate within neutrophils makes the po-
tential role of neutrophil-chemoattractant chemokines in me-
lioidosis particularly interesting (9, 36).
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